Building a Claim Stack for a Baby Skincare Line: Test Sequence and Cost from Tear-Free to Pediatric-Tested

Baby skincare claims move from the label to the lab, and the order of work matters more than the number of tests. A formula can carry six to nine claims at launch. Each one needs its own evidence file. Each file sits in a fixed place in the test sequence. This guide walks the ladder from tear-free to pediatric-tested, gives the timeline for every stage, and shows what drives the cost of baby skincare claims.

What is a claim stack for a baby skincare line?

A typical baby wash carries six to nine baby skincare claims, and each one needs its own evidence file. The stack is built from the bottom. Each claim attaches to a tier. Each tier attaches to a class of evidence. The evidence attaches to a frozen formula. Change the formula, and the upper tiers collapse. That is why human testing on an unfrozen formula wastes money.

Three things decide whether a claim can go on pack. The formula has to support the characteristic, because no test can manufacture a property the formula lacks. The evidence file then has to exist, and in the European Union it has to exist before launch. The market sets the final limit, since the same sentence can be legal in one jurisdiction and restricted in another.

The United States sets the loosest standard, which is why baby skincare claims there escape definition but not scrutiny. The FDA states that no federal standards or definitions govern the term hypoallergenic. A rule that would have required proof was struck down in Almay Inc. v. Califano, 613 F.2d 1070 (D.C. Cir. 1979). The claim survived as a marketing term.

What replaced that rule is a record-keeping duty. Under the Modernization of Cosmetics Regulation Act, the responsible person must hold adequate safety substantiation for six years. A factory that cannot produce those records on request is not a safe supplier for a baby line.

How do baby skincare claims rank from tear-free to pediatric-tested?

Baby skincare claims fall into three tiers, and the evidence bar rises with each tier.

Tier 1: mildness claims

Tier 1 covers what the product does to skin and eyes in normal use. The claims here are tear-free, pH-balanced, fragrance-free, dye-free and sulfate-free.

No law defines any of these terms, so the support is technical rather than regulatory. A tear-free claim rests on three things: the surfactant system, the pH of the finished formula, and an irritation test on a mucosal model. The ocular surface sits close to pH 7.4. A cleanser that drifts from that range stings more.

Surfactant choice decides most of the outcome. Amphoteric surfactants such as amphoacetates sit lower on the irritation scale than sulfates. Amino acid surfactants sit lower still. They also cost more per kilogram, driven by raw material cost.

Tier 2: tolerance claims

Tier 2 covers how a population reacts. The claims here are hypoallergenic, dermatologist-tested, suitable for sensitive skin and non-comedogenic.

This tier moves from a laboratory model to human skin. A patch panel under dermatological supervision is the standard instrument. A preservative challenge test on the finished formula supports it.

The European Union applies the strictest test. Article 20 of Regulation (EC) No 1223/2009 bans any claim that attributes a characteristic the product does not have. Commission Regulation (EU) No 655/2013 has set six common criteria for claim justification since 11 July 2013.

The Commission's 2017 Technical Document on Cosmetic Claims asks for three things behind a hypoallergenic claim. The formula must be designed to reduce allergenic potential. Statistically reliable data must show very low allergenic potential. Known allergens and allergen precursors must be avoided.

Tier 3: population claims

Tier 3 covers who the product was tested on. The claims here are pediatric-tested, developed with pediatricians and suitable for newborns. Buyers ask about this tier most, and it carries the thinnest public information.

Ethics review limits testing on very young infants. Nearly all pediatric-tested evidence comes from supervised use in older children. Adult panel data and a pediatrician's review of the formula sit behind it. A credible claim states the age group that was tested. A claim that implies newborn testing without an ethics-approved protocol will not survive a challenge.

Tier	Typical claims	Evidence a buyer will ask for
Tier 1, mildness	tear-free, pH-balanced, fragrance-free, dye-free, sulfate-free	surfactant system rationale, pH data for the finished formula, irritation test on a mucosal model
Tier 2, tolerance	hypoallergenic, dermatologist-tested, for sensitive skin, non-comedogenic	human patch panel under dermatological supervision, allergen screening, preservative challenge test
Tier 3, population	pediatric-tested, developed with pediatricians, suitable for newborns	supervised use in children under an ethics-approved protocol, pediatrician review, stated age group

Which test sits behind each claim?

DEVA Skincare runs 150 efficacy and safety protocols across six laboratories. Every baby skincare claims file draws on a defined subset of them.

The laboratories are organised by function, not by product. Cell level efficacy and toxicity work happens in the cell testing laboratory. The product efficacy evaluation laboratory runs the instrumental human work, including VISIA imaging across 12 skin indicators. Botanicals pass through the extraction and fermentation laboratory. Actives are quantified by HPLC, GC and UV-Vis in the analysis laboratory. Packaging ages under xenon arc light in its own laboratory, and a heavy metals laboratory closes the loop on contamination.

The core laboratory is built to CNAS standards. The factory runs 72 inspection and process control steps around it. Baby skincare claims live or die on that paperwork.

Claim	Primary protocol	Instrument or model	What you can cite
tear-free	irritation test on a mucosal model plus pH measurement	CAM irritation test, calibrated pH meter	irritation score and pH of the finished formula
mildness on infant skin	28-day human use trial	TEWL probe, texture imaging	change in barrier function across 28 days
hypoallergenic	human patch panel plus allergen screening	patch panel under dermatological supervision	no sensitisation recorded in the tested panel
preservative safety	preservative challenge test	challenge test on the finished formula	preservative system holds under microbial load
pediatric-tested	supervised use in children plus safety review	ethics-approved protocol, pediatrician review	tolerance record for the stated age group
SPF and UV claims	SPF and water resistance testing	in vitro screening plus in vivo SPF protocol	labelled SPF and water resistance rating

Why does the order of tests matter more than the total count?

One test in the wrong place voids 4 weeks of work, because a formula change resets the programme.

The order that holds up in practice runs like this. Freeze the formula and the pH first. Nothing downstream is reusable until that is settled. Run formula and stability testing next, because every human protocol depends on it.

Screen with in-vitro models while stability runs. Cell efficacy and toxicity work, plus the CAM irritation test on a mucosal model, tells you whether a human panel is worth running. Check multi-active compatibility if the formula carries more than one active.

Then run the 28-day human use trial with TEWL and texture imaging. That covers barrier function and tolerance. The patch panel comes next, for allergenic potential. The population test follows, in the age group the claim names. UV products finish with SPF and water resistance testing. Leave-on products add residue quantification.

The order is not a preference. Every human protocol consumes a panel. The worst outcome is a panel that runs on a formula stability later rejects. One well-sequenced programme costs less than two badly sequenced ones.

How long does each stage add to the timeline?

Sampling takes 1 week. Mass production takes 6 weeks after sample approval. Each test protocol runs for 4 weeks. The sequence sets the launch date for baby skincare claims, not the order quantity.

Stage	Duration	What comes next
Brief and formula design	scoped with the project	sample request
Sampling	1 week	a sample for the brand to review
Sample approval	led by the brand	the test programme starts on a frozen formula
Formula and stability testing	4 weeks	permission to run human panels
In-vitro panel	4 weeks	screening data on the actives
28-day human use trial	4 weeks	tolerance and barrier evidence with TEWL and texture imaging
Patch panel and multi-active compatibility	4 weeks	support for tolerance claims
SPF and water resistance	4 weeks	support for UV claims
Mass production	6 weeks after sample approval	finished goods

Two things shorten the calendar without weakening the evidence. The first is running protocols in parallel once the formula is frozen. A stability protocol and an in-vitro panel do not compete for the same resource. The second is keeping routine endpoints in house, which removes shipping and queue time.

The sequence still has to respect one rule. No human panel before stability passes.

What drives the cost of a claim stack?

Six variables move the cost of baby skincare claims, and only one of them is the number of tests.

Cost driver	Why it moves the number	How to control it
Number of tiers claimed	each tier adds a new class of evidence, not one more test	claim only what the positioning needs
Human panel versus instrument	human work carries recruitment, ethics and supervision cost	screen with in-vitro and CAM models first
Panel size	larger panels cost more per week and take longer to enrol	size the panel to the claim, not to the marketing line
Test duration	every protocol type runs on a 4-week clock	let protocols share one frozen formula and run in parallel
In-house versus external laboratory	external work adds handling, logistics and queue time	keep routine endpoints in a facility with its own laboratories
Reformulation	a formula change restarts the clock and voids prior results	freeze the formula before the first human test

Panel size is the variable buyers underestimate. A patch panel needs enough subjects to make the result meaningful. Every extra subject adds recruitment and supervision cost.

Test duration behaves differently. The clock is fixed at 4 weeks per protocol type. Duration does not stretch with budget. It stretches with the number of sequential blocks.

DEVA Skincare does not publish a per-test price list for baby skincare claims. The number depends on the claim set, the panel sizes, and how many protocols share one frozen formula. The test plan and its quotation are issued with the project brief.

Can a low MOQ launch carry a full baby skincare claims stack?

DEVA Skincare sets MOQ at 5,000 units for standard packaging, 10,000 for aluminium cans, 50,000 for sheet masks and 200,000 for ampoules. A first run carries the same test programme as a repeat order.

Buyers assume a small first order buys less evidence for baby skincare claims. It does not. The cost follows the claims rather than the unit count. MOQ keeps the filling line efficient. It does not ration testing.

For a first launch the sensible allocation is tier by tier. Funding Tier 1 in full comes first, because it is the cheapest evidence per unit of credibility. Tier 2 should be claimed only where the formula genuinely supports it, and Tier 3 is better deferred until the formula is frozen and repeat volume is real.

The category supports that investment. Two formulas produced at this factory sell 13 million units a year each: an infant mineral sunscreen and an amino acid foaming cleanser. A leading baby care brand that this factory serves was named Asia's number one baby sunscreen brand by Euromonitor in 2024. That certification belongs to the brand. The formulation, the testing and the manufacturing behind it are ours.

How do you keep baby care claims defensible in the EU, the US and China?

Three markets set three different bars for baby skincare claims. A range sold into all three has to clear the strictest one.

Market	Rule	What it means for a baby claim
European Union	Regulation (EC) No 1223/2009 Article 20, plus Commission Regulation (EU) No 655/2013 in force since 11 July 2013	a claim cannot attribute a characteristic the product does not have, and the evidence must sit in the Product Information File under Article 11 before launch
United States	MoCRA, enacted December 2022, plus FTC substantiation policy	safety substantiation records must be kept for six years and produced on request, and an unsupported claim is an advertising risk rather than a labelling one
China	Measures for the Administration of Cosmetic Labelling, in force 1 May 2022, plus the Provisions for the Supervision and Administration of Children's Cosmetics, in force 1 January 2022	absolute and guaranteed wording is banned, and children's cosmetics must carry the Little Golden Shield mark on the main display panel

China adds a labelling rule with no equivalent elsewhere. Children's cosmetics must carry the Little Golden Shield mark on the main display panel. The NMPA released the mark in December 2021. Newly registered or filed children's cosmetics needed it from 1 May 2022. Every children's cosmetic produced or imported after 1 May 2023 must carry it. The regulator also states that the mark is not a quality certification. It identifies a product as belonging to the children's category, and non-children's cosmetics may not use it.

Chinese rules also narrow what a baby product may claim. Products for children under 12 count as children's cosmetics. For the group aged 0 to 3 the permitted functions are cleansing, moisturising, hair care, sunscreen, soothing and keeping skin dry. Whitening, hair dyeing and perming claims are prohibited. Chinese regulatory guidance also advises against sunscreen for infants under six months, and prefers shade and clothing.

In the European Union the evidence has to exist before the product reaches the market. The responsible person must hold a Product Information File under Article 11 of Regulation (EC) No 1223/2009. A baby skincare claims file that cannot be traced to a study in that document is exposed under Article 20. This factory holds 22 special cosmetics certificates, with 21 more filed.

What should you ask a contract manufacturer before you sign?

Five questions separate a manufacturer that can build a claim stack from a filler.

Where do the routine endpoints run, in house or at an external laboratory? What is the panel size, and who supervises it? Does a reformulation restart the programme, and who pays? Which claims will the manufacturer put in writing in the technical file? How long are the records kept, and can they be produced on request?

The answers describe a facility, not a pitch. DEVA Skincare holds 70 or more granted patents with 17 more pending. It maintains more than 5,000 production-ready formulas. Its cleanrooms run at 100,000 class under ISO 22716 and GMPC certification. The company registered with the US FDA as a cosmetic manufacturer in 2023. Research and development takes 8 percent of revenue and employs 30 or more engineers and 30 or more industry specialists, in cooperation with six universities. Four plants give a combined monthly capacity above 20 million units.

That capacity matters at the moment baby skincare claims clear and the brand wants to ship. If you are building a claim stack for a baby wash, a baby lotion or an infant mineral sunscreen, send the brief through the enquiry form at the bottom of this page. We will return a test plan, the panel size behind each claim, and the sample schedule that fits it.

Is tear-free a regulated claim?

No. No market defines tear-free, so it describes a formulation outcome rather than a certified property. Support comes from the surfactant system, the pH of the finished formula and an irritation test on a mucosal model. Keep the wording modest: reduced eye irritation in normal use, not zero risk.

What is the difference between hypoallergenic and pediatric-tested?

Hypoallergenic describes reduced allergenic potential in the formula. Pediatric-tested describes the population that tolerated it. A product can be hypoallergenic with no child data, and pediatric-tested without a formal allergenic potential study. Ask for both records separately, and check which age group was actually tested.

How long does a full claim stack take?

Sampling takes 1 week and each test protocol runs 4 weeks. Protocols that share a frozen formula can run in parallel, so a Tier 1 and Tier 2 programme normally finishes inside one to two 4-week blocks, followed by 6 weeks of mass production after sample approval.

Can you test baby products on infants?

Ethics approval limits testing on very young infants. Most pediatric-tested evidence comes from supervised use in older children, combined with adult panel data and a pediatrician's review of the formula. Any claim must state the age group that was tested, and no claim should imply newborn data that does not exist.

Does a low MOQ order still qualify for full claim testing?

Yes. The test programme follows the claim set, not the order quantity. DEVA Skincare sets MOQ at 5,000 units for standard packaging, and a first run carries the same protocols as a repeat order. Budget is set by the claims you choose, not by the number of units.

Do you need a separate test for every claim?

No. One protocol can support several claims when they share an endpoint, such as a 28-day use trial covering barrier function and tolerance in one panel. The rule is one evidence file per characteristic, not one test per phrase on the pack, so map the endpoints before you brief the laboratory.